Premier Asset Management LLC Invests $657,000 in Dermira Inc (NASDAQ:DERM) Stock

Premier Asset Management LLC bought a new stake in shares of Dermira Inc (NASDAQ:DERM) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 91,298 shares of the biopharmaceutical company’s stock, valued at approximately $657,000. Premier Asset Management LLC owned about 0.22% of Dermira at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky increased its stake in Dermira by 25.2% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,915 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 8,640 shares during the period. MetLife Investment Advisors LLC increased its stake in shares of Dermira by 55.6% during the 3rd quarter. MetLife Investment Advisors LLC now owns 28,224 shares of the biopharmaceutical company’s stock worth $308,000 after purchasing an additional 10,085 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Dermira by 356.7% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 10,085 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Dermira during the 3rd quarter worth $128,000. Finally, Nomura Holdings Inc. boosted its holdings in shares of Dermira by 18.5% during the 4th quarter. Nomura Holdings Inc. now owns 75,696 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 11,836 shares during the period. 68.99% of the stock is owned by institutional investors and hedge funds.

Shares of Dermira stock traded down $0.18 during mid-day trading on Monday, reaching $11.49. 1,318,000 shares of the stock were exchanged, compared to its average volume of 1,889,392. The stock has a market capitalization of $630.45 million, a P/E ratio of -2.19 and a beta of 1.45. The company has a quick ratio of 8.48, a current ratio of 8.70 and a debt-to-equity ratio of 5.21. Dermira Inc has a fifty-two week low of $6.00 and a fifty-two week high of $15.48.

Dermira (NASDAQ:DERM) last announced its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.05. Dermira had a negative net margin of 523.25% and a negative return on equity of 309.23%. On average, equities analysts anticipate that Dermira Inc will post -5.25 earnings per share for the current year.

DERM has been the subject of several recent analyst reports. BidaskClub downgraded shares of Dermira from a “buy” rating to a “hold” rating in a report on Friday, December 28th. Cantor Fitzgerald set a $20.00 price objective on shares of Dermira and gave the stock a “buy” rating in a report on Friday, December 28th. ValuEngine downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Zacks Investment Research raised shares of Dermira from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a report on Thursday, January 10th. Finally, Raymond James raised shares of Dermira from an “underperform” rating to a “market perform” rating and set a $6.71 price target for the company in a report on Thursday, January 17th. Three analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $17.36.

In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the sale, the insider now owns 43,900 shares in the company, valued at approximately $658,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 14.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/15/91298-shares-in-dermira-inc-derm-purchased-by-premier-asset-management-llc.html.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Recommended Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.